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1. INTRODUCTION {#ccd27807-sec-0006}
===============

Interventional cardiovascular procedures are often essential for the diagnosis and treatment of coronary artery disease (CAD) and peripheral arterial disease (PAD). According to a recent American Heart Association update, approximately 1 million cardiac catheterizations in addition to half a million percutaneous coronary interventions (PCI) are performed annually in the United States (US).[1](#ccd27807-bib-0001){ref-type="ref"} Contrast media play an important role in these procedures and are classified according to their ionic and osmotic properties. Low osmolar contrast media (LOCMs) include iohexol (Omnipaque), a nonionic, iodinated LOCM. Iohexol as well as other nonionic LOCMs (ioversol \[Optiray\], ioxilan \[Oxilan\], iopamidol \[Isovue\] and ioxaglate \[Hexabrix\], an ionic LOCM) are commonly used contrast media for computed tomography (CT) imaging and can be administered either intra‐arterially or intravenously.

Although LOCMs have a good safety profile, the possibility of adverse reactions such as acute kidney injury (AKI) should always be considered.[2](#ccd27807-bib-0002){ref-type="ref"}, [3](#ccd27807-bib-0003){ref-type="ref"} The development of contrast‐induced AKI (CI‐AKI) has been widely documented in the literature and the risk factors of CI‐AKI are generally known to include the presence of diabetes and the patient\'s estimated glomerular filtration rate.[4](#ccd27807-bib-0004){ref-type="ref"} CI‐AKI is defined as acute renal insufficiency occurring in a patient with normal renal function preceding CM administration or when a patient with chronic renal insufficiency experiences a significant worsening of renal function after CM administration. In some patients, CI‐AKI has been associated with progression to advanced stages of chronic kidney disease and an increased risk for major adverse cardiac events (MACE).[5](#ccd27807-bib-0005){ref-type="ref"}, [6](#ccd27807-bib-0006){ref-type="ref"} For example, contemporary insights from the NCDR Cath‐PCI registry suggest worsened incidence of bleeding, MI, and death attributed to the development of AKI after PCI.[7](#ccd27807-bib-0007){ref-type="ref"}

There are a considerable number of reports evaluating the safety of contrast media, though the study methods and findings are variable.[8](#ccd27807-bib-0008){ref-type="ref"}, [9](#ccd27807-bib-0009){ref-type="ref"}, [10](#ccd27807-bib-0010){ref-type="ref"}, [11](#ccd27807-bib-0011){ref-type="ref"}, [12](#ccd27807-bib-0012){ref-type="ref"}, [13](#ccd27807-bib-0013){ref-type="ref"} There are several meta‐analyses of randomized controlled trials (RCT), comparing CI‐AKI rates between LOCMs and iso‐osmolar CM (IOCMs).[8](#ccd27807-bib-0008){ref-type="ref"}, [11](#ccd27807-bib-0011){ref-type="ref"}, [12](#ccd27807-bib-0012){ref-type="ref"}, [13](#ccd27807-bib-0013){ref-type="ref"} Heinrich and coauthors published a meta‐analysis in 2009 which indicated that iohexol had higher rates of CI‐AKI when compared to IOCMs for coronary angiography. A similar study in 2009 showed that both iohexol and ioxaglate had higher rates of CI‐AKI when compared with IOCMs.[13](#ccd27807-bib-0013){ref-type="ref"} Citing these two findings, the 2009 American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[14](#ccd27807-bib-0014){ref-type="ref"} recommend the use of LOCMs other than iohexol and ioxaglate for coronary angiography procedures. However, the guidelines have since changed. The 2011 ACC/AHA guidelines no longer differentiated among LOCMs, and stated "these clinical inferences must be tempered by the relative paucity of head‐to‐head trials comparing CIN rates among the various contrast media and the variability in results".[15](#ccd27807-bib-0015){ref-type="ref"} Recommendations now encompass three pillars: risk assessment, importance of hydration strategies, and contrast media volume reduction. In a more recent (2012) large retrospective observational study, the safety of various LOCMs was evaluated in patients undergoing inpatient coronary angiography with or without PCI, no apparent clinical advantage was evident amongst LOCMs in regards to in‐hospital death, need for hemodialysis, or readmission for CI‐AKI.[10](#ccd27807-bib-0010){ref-type="ref"}

With this background, we set out to describe current outcomes observed in patients receiving various LOCMs from a very large database. The primary objective of this study was to retrospectively assess the rate of major adverse renal or cardiac events (MARCE) when iohexol, compared to other LOCMs, is used during interventional cardiovascular procedures across different hospitals in a real‐world setting with, data permitting, direct comparisons of iohexol to iopamidol and ioversol.

2. METHODS {#ccd27807-sec-0007}
==========

2.1. Data source {#ccd27807-sec-0008}
----------------

Data for this study were derived from the Premier Hospital Database, from January 1, 2010 through September 30, 2015. The database contains data from more than 350 million patient encounters, or one in every five discharges in the US.[16](#ccd27807-bib-0016){ref-type="ref"} The database includes data from standard hospital discharge files, including a patient\'s demographic information, diagnoses, and information on billed services, including medications, laboratory, diagnostics and therapeutic services in deidentified patient daily service records. In addition, information on hospital characteristics, including geographic location, bed size and teaching status is also available. The Premier Hospital Database has been used in over 430 peer reviewed publications. The methods used in this paper provide a general framework for analysis of this database.

Preliminary comparisons between patient and hospital characteristics for the hospitals that submit data to Premier and those of the probability sample of hospitals and patients selected for the National Hospital Discharge Survey (NHDS)[17](#ccd27807-bib-0017){ref-type="ref"} suggest that the patient populations are similar with regard to patient age, gender, length of stay, mortality, primary discharge diagnosis, and primary procedure groups. It should be noted that the number of participating hospitals within the database may change over time during the study period.

All data used to perform this analysis were de‐identified and accessed in compliance with the Health Insurance Portability and Accountability Act. As a retrospective analysis of a deidentified database, the research was exempt from IRB review under 45 CFR 46.101(b) (4).

2.2. Inclusion criteria and cohort definitions {#ccd27807-sec-0009}
----------------------------------------------

Inpatient visits with a primary interventional cardiovascular procedure (Supporting Information Appendix [A](#ccd27807-supitem-0001){ref-type="supplementary-material"} for coding) were included for analysis. Patient encounters were required to have a record of a single, known LOCM (iohexol, ioversol, ioxilan, ioxaglate, or iopamidol). Visits with an unknown type of contrast (not enough detail in the billing description), IOCM, multiple types of contrast, or no contrast at all were excluded. The attrition diagram (Figure [1](#ccd27807-fig-0001){ref-type="fig"}) shows the implementation of the inclusion criteria down to the final sample.

![Attrition diagram. LOCM: low osmolar contrast media including ioversol, ioxilan, ioxaglate, or iopamidol](CCD-93-E90-g001){#ccd27807-fig-0001}

2.3. Outcomes {#ccd27807-sec-0010}
-------------

The primary outcome of interest for this study was the composite end point MARCE. MARCE was defined as having occurred in any inpatient visit if one or more of the following events were recorded: renal failure with dialysis, AKI with and without dialysis, CI‐AKI, acute myocardial infarction, angina, stent occlusion/thrombosis, stroke, transient ischemic attack (TIA), or death. To increase the likelihood that the MARCE events were associated with the hospitalization and not conditions present upon admission, events were identified as being an outcome of interest if two conditions were met: (1) record of the event of interest during hospitalization and (2) the event of interest was not coded as present on admission.

2.4. Univariate comparisons {#ccd27807-sec-0011}
---------------------------

Patient demographics (age, race, gender, marital status, region, and insurance type), the Elixhauser Comorbidity Index[18](#ccd27807-bib-0018){ref-type="ref"} (Supporting Information Appendix [B](#ccd27807-supitem-0002){ref-type="supplementary-material"}), hospital characteristics, and MARCE events (Supporting Information Appendix [C](#ccd27807-supitem-0003){ref-type="supplementary-material"}) were summarized with percentages by each cohort: iohexol vs. other LOCMs. Univariate tests (*t* tests, chi‐squared) were performed to show if significant differences existed between the two cohorts before modeling.

2.5. Multivariable models {#ccd27807-sec-0012}
-------------------------

The decision to utilize a particular product or drug during a hospital visit may depend on formal hospital guidelines, patient comorbidities, physician practice patterns or preferences, negotiated reimbursement schedules with insurance companies, and other local (geographic and/or hospital) characteristics. These elements are mostly unobservable for the purpose of statistical inference. In this study, multivariable regression analysis was conducted using the hospital fixed‐effects specification to assess the relationship between the type of CM used and MARCE events. The hospital fixed‐effect specification methodology was chosen to control for time‐invariant within‐hospital variation that are otherwise unobservable in the choice of CM, such as hospital protocols which specify which contrast media is used. The fixed‐effects model allowed for control of hospitals\' unobserved internal rules on product assignment (hospital indicator). In addition, all models controlled for the following covariates: patient demographics (year, age, gender, race marital status, admission type, and insurance group), comorbidities (categories of the Elixhauser Comorbidity Index) and reason for hospitalization (primary procedure and primary diagnosis).

2.6. Sensitivity analysis {#ccd27807-sec-0013}
-------------------------

The other LOCM cohort was further subdivided by each of the individual LOCMs that comprised the group: ioversol, ioxilan, ioxaglate, and iopamidol. Separate models, sample size permitting, were estimated to assess the relationship between MARCE events and iohexol vs. each individual LOCM. Each model used the same hospital fixed‐effect specification methodology along with controlling for patient demographics, patient comorbidities and reason for hospitalization.

3. RESULTS {#ccd27807-sec-0014}
==========

A total of 1,419,509 inpatient visits from January 2010 through September 2015 met the initial inclusion criterion, having a record of a primary interventional cardiology procedure (Figure [1](#ccd27807-fig-0001){ref-type="fig"}). Visits were further subdivided into five mutually exclusive categories: (1) no record of contrast usage; (2) visits with multiple contrast usage; (3) visits with contrast usage for which type of contrast was not discernable; (4) visits with a record of IOCM (11%) instead of LOCM; (5) record of single known LOCM. A total of 458,091 (32%) patient encounters met all of the inclusion criteria (primary interventional cardiology procedure with use of a known LOCM). These were divided into two cohorts: iohexol 118,476 (26%) and all other LOCMs 339,615 (74%). The other LOCMs cohort had the following distribution of CM: ioversol (55%), iopamidol (43%), ioxilan (2%), and ioxaglate (0.002%).

3.1. Univariate {#ccd27807-sec-0015}
---------------

Univariate analysis of the cohorts found no significant difference in the mean age of the cohorts, but statistically significant differences in other demographic characteristics existed (Table [1](#ccd27807-tbl-0001){ref-type="table"}); however, many of these differences were quite small and potentially due to the very large sample sizes. Iohexol had higher rates of use in Caucasian and male patients. There were also slight differences in insurance provider and admission type. Patient comorbidity scores were slightly higher in the iohexol cohort, whereby iohexol cohort had significantly higher rates of valvular disease (17% vs. 14%, *P* ≤ 0.0001), cardiac arrhythmia (41% vs. 38%, *P* ≤ 0.0001), and depression (10% vs. 9%, *P* ≤ 0.0001) (Table [2](#ccd27807-tbl-0002){ref-type="table"}). While the other LOCMs cohort had significantly higher rates of peripheral vascular disorders (18% vs. 16%, *P* ≤ 0.0001), complicated hypertension (17% vs. 15%, *P* ≤ 0.0001), and a history of chronic renal failure upon admission to the hospital (16% vs. 14%, *P* ≤ 0.0001).

###### 

Patient visit baseline demographics

                     Iohexol   Other LOCMs   *P*‐value         
  ------------------ --------- ------------- ----------- ----- ---------
  Age                                                          0.3525
  Median             65                      65                
  Mean               64.9                    64.9              
  Std. dev.          13.08                   13.07             
  Age group                                                    0.0694
  \<18               280       0%            913         0%    
  18--29             614       1%            1,632       0%    
  30--39             2,406     2%            6,904       2%    
  40--49             10,690    9%            30,269      9%    
  50--59             25,668    22%           72,867      21%   
  60--69             33,752    28%           97,687      29%   
  70--79             28,130    24%           81,174      24%   
  80 or older        16,936    14%           48,169      14%   
  Race                                                         \<.0001
  Caucasian          90,443    76%           249,213     73%   
  African‐American   11,587    10%           35,601      10%   
  Other              16,446    14%           54,801      16%   
  Gender                                                       \<.0001
  Female             41,234    35%           120,999     36%   
  Male               77,241    65%           218,614     64%   
  Unknown            1         0%            2           0%    
  Insurance                                                    \<.0001
  Commercial         6,421     5%            15,607      5%    
  Medicare           67,091    57%           190,232     56%   
  Medicaid           8,296     7%            24,976      7%    
  Managed care       25,460    21%           77,482      23%   
  Other              11,208    9%            31,318      9%    
  Admission type                                               \<.0001
  Emergency          60,628    51%           182,853     54%   
  Urgent             26,754    23%           64,574      19%   
  Elective           30,817    26%           88,330      26%   
  Other/unknown      277       0%            3,858       1%    

###### 

Patient baseline comorbid conditions

                                              Iohexol   Other LOCMs   *P*‐value         
  ------------------------------------------- --------- ------------- ----------- ----- ---------
  Elixhauser comorbidities                                                              
  Congestive heart failure                    31,120    26%           87,272      26%   0.0001
  Cardiac arrhythmia                          49,093    41%           129,093     38%   \<.0001
  Valvular disease                            20,119    17%           48,875      14%   \<.0001
  Pulmonary circulation disorders             6,777     6%            19,401      6%    0.9237
  Peripheral vascular disorders               19,335    16%           62,682      18%   \<.0001
  Hypertension (uncomplicated)                73,312    62%           209,089     62%   0.0566
  Hypertension (complicated)                  17,781    15%           56,072      17%   \<.0001
  Paralysis                                   1,513     1%            3,797       1%    \<.0001
  Other neurological disorders                6,985     6%            18,646      5%    \<.0001
  Chronic pulmonary disease                   27,871    24%           81,730      24%   0.0002
  Diabetes (uncomplicated)                    36,330    31%           106,824     31%   \<.0001
  Diabetes (complicated)                      6,654     6%            20,155      6%    \<.0001
  Hypothyroidism                              12,995    11%           36,127      11%   0.0015
  Renal failure                               16,875    14%           53,447      16%   \<.0001
  Liver disease                               3,045     3%            8,485       2%    0.1748
  Peptic ulcer disease (excluding bleeding)   740       1%            2,256       1%    0.1446
  AIDS/HIV                                    189       0%            511         0%    0.4917
  Lymphoma                                    540       0%            1,597       0%    0.5297
  Metastatic cancer                           474       0%            1,453       0%    0.2037
  Solid tumor without metastasis              1,606     1%            4,769       1%    0.2180
  Rheumatoid arthritis collagen               2,457     2%            6,427       2%    \<.0001
  Coagulopathy                                7,562     6%            20,823      6%    0.0020
  Obesity                                     21,080    18%           60,936      18%   0.2461
  Weight loss                                 2,980     3%            7,770       2%    \<.0001
  Fluid and electrolyte disorders             21,400    18%           60,178      18%   0.0078
  Blood loss anemia                           717       1%            2,404       1%    0.0002
  Deficiency anemia                           2,167     2%            6,738       2%    0.0009
  Alcohol abuse                               3,969     3%            10,423      3%    \<.0001
  Drug abuse                                  3,035     3%            8,127       2%    0.0012
  Psychoses                                   963       1%            2,736       1%    0.8114
  Depression                                  11,596    10%           29,058      9%    \<.0001
  Elixhauser comorbidity index                                                          \<.0001
  Mean                                        3.5                     3.4               
  Std. dev.                                   2.22                    2.19              

The iohexol cohort had a significantly different distribution of hospital region (*P* ≤ 0.0001), compared with the other LOCMs cohort, with more visits coming from the northeast and west (Table [3](#ccd27807-tbl-0003){ref-type="table"}). Also, the iohexol cohort had more visits from urban hospitals (*P* ≤ 0.0001), teaching hospitals (*P* ≤ 0.0001), and larger bed size hospitals (*P* ≤ 0.0001). The univariate MARCE rates were slightly higher in the other LOCMs cohort (7.9% vs. 7.7%, *P* = 0.0077) before multivariable modeling (Table [4](#ccd27807-tbl-0004){ref-type="table"}).

###### 

Hospital baseline characteristics

                  Iohexol   Other LOCMs   *P*‐value         
  --------------- --------- ------------- ----------- ----- ---------
  Census region                                             \<.0001
  Northeast       23,928    20%           48,535      14%   
  Midwest         21,323    18%           60,034      18%   
  South           54,570    46%           194,610     57%   
  West            18,655    16%           36,436      11%   
  Location                                                  \<.0001
  Urban           111,774   94%           306,937     90%   
  Not urban       6,702     6%            32,678      10%   
  Type                                                      \<.0001
  Teaching        71,661    60%           162,953     48%   
  Non‐teaching    46,815    40%           176,662     52%   
  Bed count                                                 \<.0001
  0--99           865       1%            5,715       2%    
  100--199        9,741     8%            23,291      7%    
  200--299        9,998     8%            42,733      13%   
  300--399        16,922    14%           79,258      23%   
  400--499        21,512    18%           56,274      17%   
  500+            59,438    50%           132,344     39%   

###### 

Rates of adverse events prior to multivariable modeling

                                          Iohexol   Other LOCMs   *P*‐value          
  --------------------------------------- --------- ------------- ----------- ------ ---------
  *Adverse events*                                                                   
  MARCE                                   9,076     7.7%          26,837      7.9%   0.0077
  AMI                                     1,131     1.0%          2,822       0.8%   \<.0001
  Angina                                  375       0.3%          1,212       0.4%   0.0418
  Stent                                   490       0.4%          1,601       0.5%   0.011
  Stroke                                  1,133     1.0%          3,153       0.9%   0.3903
  TIA                                     163       0.1%          531         0.2%   0.1526
  Renal composite                         4,643     3.9%          14,051      4.1%   0.0011
  Acute kidney injury                     4,627     3.9%          13,999      4.1%   0.0012
  Acute kidney injury with dialysis       297       0.3%          895         0.3%   0.4547
  Acute kidney injury, contrast induced   244       0.2%          976         0.3%   \<.0001
  Renal failure                           17        0.0%          54          0.0%   0.7119
  Death                                   2,349     2.0%          6,965       2.1%   0.1523

Abbreviations: AMI, acute myocardial infarction; TIA, transient ischemic attack.

3.2. Multivariable {#ccd27807-sec-0016}
------------------

Using the hospital fixed‐effects specification, while controlling for patient demographics, comorbid conditions, and primary diagnosis/procedure, differences in MARCE rates between iohexol and other LOCMs were not statistically significant (Figure [2](#ccd27807-fig-0002){ref-type="fig"}). When analyzing the individual components of the MARCE composite endpoint, iohexol had a slightly higher estimated incidence of stent occlusion/thrombosis (0.0013 \[0.0004, 0.0021\]) and a lower estimated incidence of angina (−0.0024 \[−0.0031, −0.0016\]). All other components of MARCE were not statistically significant when comparing iohexol vs. other LOCMs.

![Multivariable model results---iohexol vs. other LOCMs. The parameter estimates with confidence intervals from multivariable modeling which used the hospital fixed‐effects specification, and controlled for patient demographics, comorbid conditions, and primary diagnosis/procedure, are shown. The composite endpoint of the rate of MARCE was found to have no statistically significant differences between iohexol and other LOCMs. Rates of the individual components of the MARCE composite endpoint were analyzed, iohexol had a slightly higher estimate of stent occlusion/thrombosis (0.0013 \[0.0004, 0.0021\]) and a lower estimate of angina (−0.0024 \[−0.0031, −0.0016\]). All other components of MARCE were not statistically significant when comparing iohexol vs. other LOCMs. MARCE: major adverse renal or cardiac events, LOCM: low osmolar contrast media, AMI: acute myocardial infarction, TIA: transient ischemic attack, AKI: acute kidney injury, CI‐AKI: contrast induced acute kidney injury](CCD-93-E90-g002){#ccd27807-fig-0002}

3.3. Sensitivity analysis {#ccd27807-sec-0017}
-------------------------

As a sensitivity analysis, the MARCE and renal composite endpoints were analyzed separately comparing iohexol vs. ioversol and iohexol vs. iopamidol without finding significant differences (Figure [3](#ccd27807-fig-0003){ref-type="fig"}). There was insufficient sample size to directly compare iohexol with ioxaglate or ioxilan.

![Multivariable model results---iohexol vs. ioversol and iopamidol. The figure shows the parameter estimates with confidence intervals from of a sensitivity analysis in which the MARCE and renal composite endpoints were analyzed separately comparing iohexol to ioversol and iohexol to iopamidol. The sensitivity analysis used multivariable modeling with hospital fixed‐effects specification, controlled for patient demographics, comorbid conditions, and primary diagnosis/procedure. No differences were found in the rate of MARCE or renal adverse events between iohexol and ioversol nor between iohexol and iopamidol. MARCE: major adverse renal or cardiac events](CCD-93-E90-g003){#ccd27807-fig-0003}

4. DISCUSSION {#ccd27807-sec-0018}
=============

Despite prior concerns regarding iohexol, we found no evidence of increased MARCE among those who received iohexol as compared to other LOCMs. While many prior studies have evaluated the safety profile of LOCMs using serum creatinine, this is the first to use real‐world data to compare clinical outcomes when using iohexol vs. other LOCMs during interventional cardiovascular procedures.

In our study, there was no difference among LOCMs for most individual components of the composite MARCE endpoint, including stroke, TIA, AKI, renal failure, and death. However, results of the univariate analysis indicated patients who received iohexol had lower AKI and CI‐AKI. Results of the multivariable analysis indicated there was no statistically significant difference in the risk of MARCE when iohexol was used compared to other LOCMs. A sensitivity analysis also was conducted comparing iohexol to each of the other LOCMs individually, which showed a non‐significant difference in MARCE rates between iohexol and ioversol or iopamidol. There was insufficient data available for a direct head‐to‐head comparison between iohexol and ioxaglate or ioxilan.

Adverse event rates associated with LOCMs have been studied extensively[8](#ccd27807-bib-0008){ref-type="ref"}, [9](#ccd27807-bib-0009){ref-type="ref"}, [10](#ccd27807-bib-0010){ref-type="ref"}, [11](#ccd27807-bib-0011){ref-type="ref"}, [12](#ccd27807-bib-0012){ref-type="ref"}, [13](#ccd27807-bib-0013){ref-type="ref"} and while this study shows no difference in the rate of the MARCE composite, results of prior published studies have varied. Meta‐analyses of available RCTs have been published comparing LOCMs and IOCMs,[8](#ccd27807-bib-0008){ref-type="ref"}, [11](#ccd27807-bib-0011){ref-type="ref"}, [12](#ccd27807-bib-0012){ref-type="ref"}, [13](#ccd27807-bib-0013){ref-type="ref"} the overlap in time‐periods and inclusion criteria led to the use of some of the same trials in multiple studies. In a meta‐analysis of CI‐AKI rates between LOCMs and an IOCM, no difference was reported between CI‐AKI rates with all LOCMs grouped together, a subgroup analysis separately comparing iohexol with IOCM and all other LOCMs (grouped together) with IOCMs found iohexol had significantly higher CI‐AKI rates.[12](#ccd27807-bib-0012){ref-type="ref"} The group containing all other LOCMs was still not statistically different. A very similar meta‐analysis showed that both iohexol and ioxaglate had higher CI‐AKI rates than an IOCM.[13](#ccd27807-bib-0013){ref-type="ref"} It is important to note that there is no published RCT directly comparing individual LOCMs in a head‐to‐head fashion. Prior published results performed indirect comparisons, whereas the current study directly compared various LOCMs head‐to‐head in a real‐world setting. Moreover, the published meta‐analyses only evaluate CI‐AKI as a biochemical endpoint, whereas this study evaluated a clinical composite endpoint capturing many different adverse events not evaluated in prior studies.

Results of this analysis confirm and extend the results of a large retrospective, propensity‐matched observational study[10](#ccd27807-bib-0010){ref-type="ref"} which revealed no difference in hemodialysis, readmission due to CI‐AKI, or mortality between iohexol, ioversol or iopamidol. Our study adds to the literature with the composite endpoint of MARCE and with detailed statistical management of patient demographics, patient comorbidities, reason for hospitalization and within hospital variation to arrive at independent measures of risk for each CM. The MARCE events we reported occurred in the same visit as contrast exposure and thus it is likely that the procedure and use of contrast were clinically associated in some way with the MARCE event(s) that occurred.

4.1. Strengths and limitations {#ccd27807-sec-0019}
------------------------------

The strengths of this study include the use of a comprehensive data source and use of the hospital fixed‐effect specification methodology that controlled for time‐invariant within hospital variation that is otherwise unobservable, such as physician preferences and internal protocols. This study has limitations, which are inherent to retrospective database analyses. These include the unit of inference, which was the visit and not the patient, and the lack of longitudinal tracking of a patient. Thus, it was not possible to determine if events occurred after the patient was discharged. Laboratory values were not available, thus we could not define CI‐AKI by serum creatinine levels, and rather the outcome was defined by the ICD‐9 code for CI‐AKI which may underestimate the occurrence of this event. The data source for this study was the Premier Healthcare Database which represents 20% of all inpatient discharges in the US; however, given its reliance on ICD‐9 codes, even with validation efforts, the risk of coding errors cannot be completely eliminated. Additionally, CM volume is not a data point that is captured in this hospital billing database. Attempts to identify the CM volume used, through text mining the chargemaster of this database, were not successful at a high enough frequency, resulting in a large portion of missing data for patients. Even if this portion of data was not missing, there is a potential of an overestimation based on use of the total amount that is charged for the visit, and not what was actually administered. This overestimation could be biased toward each type of CM differently, given the variation in package sizing.

5. CONCLUSION {#ccd27807-sec-0020}
=============

This analysis used multivariable modeling to control for differences in hospital characteristics, patient demographics and comorbidities across the LOCM cohorts. This retrospective study found no statistically significant clinical differences in the rate of MARCE among those given iohexol compared to patients who received other LOCMs combined and specifically vs. ioversol and iopamidol for inpatient interventional cardiovascular procedures.
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